Voorbeelden van het gebruik van Aclidinium in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Aclidinium is rapidly
The recommended dose is one inhalation of 322 µg aclidinium twice daily.
Each delivered dose contains 375 micrograms aclidinium bromide equivalent to 322 micrograms of aclidinium.
The main plasma protein that binds aclidinium is albumin.
Aclidinium is administered by means of the Genuair® multi-dose powder inhaler.
Brimica Genuair contains two bronchodilators: aclidinium is a long-acting muscarinic antagonist(also known as an anticholinergic)
Following inhalation of Brimica Genuair 340/12 micrograms, aclidinium and formoterol showed terminal elimination half-lives of approximately 5 h and 8 h, respectively.
Following intravenous administration of radiolabelled aclidinium 400 micrograms to healthy subjects,
In vitro studies have shown that aclidinium or its metabolites are not substrates or inhibitors of P-glycoprotein.
Whole lung deposition of inhaled aclidinium via Genuair averaged approximately 30% of the metered dose.
It is unknown whether aclidinium(and/or its metabolites)
As Brimica Genuair contains aclidinium and formoterol, the type
in vivo studies showed rapid, dose-dependent and long-lasting inhibition by aclidinium of acetylcholine-induced bronchoconstriction.
contains 375 µg aclidinium bromide equivalent to 322 µg of aclidinium.
The fraction of the inhaled dose that reaches the systemic circulation as unchanged aclidinium is very low at less than 5.
no dosage adjustment is warranted for aclidinium/formoterol.
The peak plasma concentrations at steady state of aclidinium and formoterol observed in patients with COPD treated with Brimica Genuair twice daily for 5 days were reached within 5 minutes post-inhalation
In vitro studies have shown that aclidinium at the therapeutic dose
When aclidinium and formoterol were administered in combination by the inhaled route,
The low absolute bioavailability of inhaled aclidinium(< 5%) is because aclidinium undergoes extensive systemic